These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36451799)

  • 21. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing health through the rapidly developing fields of comparative and cost-effectiveness.
    Annemans L
    J Comp Eff Res; 2012 Nov; 1(6):479-80. PubMed ID: 24236465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of comparative effectiveness research to the future of healthcare evaluation and delivery.
    Lyman GH; Dormer L
    J Comp Eff Res; 2014 Sep; 3(5):455-7. PubMed ID: 25350796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 27. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Short-run and Long-run Effects of Covid-19 on Energy and the Environment.
    Gillingham KT; Knittel CR; Li J; Ovaere M; Reguant M
    Joule; 2020 Jul; 4(7):1337-1341. PubMed ID: 32835174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
    Berger ML
    J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions.
    Fugel HJ; Nuijten M; Faulkner E
    J Med Econ; 2014 May; 17(5):305-11. PubMed ID: 24654841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
    Beck E; Biundo E; Devlin N; Doherty TM; Garcia-Ruiz AJ; Postma M; Sheikh S; Smela B; Toumi M; Wasem J; Nolan T; Salisbury D
    Vaccine; 2022 Jun; 40(30):4008-4016. PubMed ID: 35618559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts.
    Postma M; Biundo E; Chicoye A; Devlin N; Mark Doherty T; Garcia-Ruiz AJ; Jaros P; Sheikh S; Toumi M; Wasem J; Beck E; Salisbury D; Nolan T
    Vaccine; 2022 Jun; 40(30):3999-4007. PubMed ID: 35597688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
    Garrison LP; Pauly MV; Willke RJ; Neumann PJ
    Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis.
    Neumann PJ; Garrison LP; Willke RJ
    Value Health; 2022 Apr; 25(4):558-565. PubMed ID: 35279370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interview: commercial translation of cell-based therapies and regenerative medicine: learning by experience. Interview by Emily Culme-Seymour.
    Haseltine WA
    Regen Med; 2011 Jul; 6(4):431-5. PubMed ID: 21749201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 9.
    Simpson A; Ramagopalan SV
    J Comp Eff Res; 2022 Nov; 11(16):1147-1149. PubMed ID: 35998008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Women's health research in the last four decades. Interview by Natasha Leeson.
    Weiss G
    Womens Health (Lond); 2014 Jan; 10(1):13-6. PubMed ID: 24328595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019.
    Inotai A; Németh B
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):379-381. PubMed ID: 31159614
    [No Abstract]   [Full Text] [Related]  

  • 40. Innovation within a university setting.
    Wynne EK; Krummel TM
    Surgery; 2016 Dec; 160(6):1427-1431. PubMed ID: 27866639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.